Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.93 |
| ▸ | BCHE | P06276 | 10/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233408 | 0.93 | PARP14 (0.91) | PARP14BCHEHPGDSCHRM2HTR1A | |
| Fumaric Acid SCHEMBL6631974 | 0.93 | PARP14 (0.81) | PARP14BCHEHPGDSCHRM2HTR1A | |
| Fumaric Acid SCHEMBL6631979 | 0.93 | PARP14 (0.81) | PARP14BCHEHPGDSCHRM2HTR1A | |
| Fumaric Acid SCHEMBL7225813 | 0.89 | PARP14 (0.86) | PARP14BCHEHPGDSCHRM2HTR1A | |
| Fumaric Acid SCHEMBL7225810 | 0.89 | PARP14 (0.86) | PARP14BCHEHPGDSCHRM2HTR1A | |
| SCHEMBL6631009 | 0.83 | PARP14 (0.98) | PARP14BCHEHPGDSCHRM2HTR1A | |
| SCHEMBL7233388 | 0.82 | PARP14 (1.00) | PARP14BCHEHPGDSCHRM2HTR1A | |
| SCHEMBL6621938 | 0.82 | PARP14 (0.64) | PARP14BCHEHPGDSCHRM2HTR1A | |
| SCHEMBL7227564 | 0.81 | PARP14 (0.94) | PARP14BCHEHPGDSCHRM2HTR1A | |
| SCHEMBL6616803 | 0.81 | PARP14 (0.65) | PARP14BCHEHPGDSCHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610694-B1 | Suppressing histamine and/or eosinophil chemotaxis; treating allergic diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-26 | — | — | US | claimed |
| EP-1120418-A1 | FUSED PYRIDAZINE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | claimed |
| US-20040254189-A1 | Jnk inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040137052-A1 | mixture of a drug having anti-allergy, anti-histamine, anti-inflammatory, anti-PAF (platelet-aggregating factor) or eosinophile chemotaxis inhibiting activity and an acid; dosage form; excellent in the digestive tract absorbability and stability | TAKEDA CHEMICAL INDUSARIES LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1426050-A1 | JNK INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6610694-B1 | Suppressing histamine and/or eosinophil chemotaxis; treating allergic diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| EP-1120418-A1 | FUSED PYRIDAZINE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
| JP-2000178277-A | CONDENSED PYRIDAZINE COMPOUND, ITS PRODUCTION AND APPLICATION | TAKEDA CHEM IND LTD | 2000-06-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254189-A1 | Jnk inhibitors | AR, MAPK1, MAPK3 | PARP14 1524/4885BCHE 4268/4885HPGDS 1541/4885 |
| US-20040137052-A1 | mixture of a drug having anti-allergy, anti-histamine, anti-inflammatory, anti-PAF (platelet-aggregating factor) or eosinophile chemotaxis inhibiting activity and an acid; dosage form; excellent in the digestive tract absorbability and stability | PLA2G7, HRH2, PAFAH1B2 | PARP14 1027/4885BCHE 747/4885HPGDS 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.